Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, December 10, 2025

Vaccines Against Dementia? New Evidence Reveals Stunning Protection!

 Your competent? doctor got you the Shingrix vaccine immediately upon availability, right? And has a protocol to get you the shots while still in the hospital!

  • Shingrix vaccine (7 posts to October 2017)
  • Vaccines Against Dementia? New Evidence Reveals Stunning Protection!

    Could a shingles shot prevent and/or slow the development of dementia? New Research expands the case for vaccines against dementia.
    For decades, drug companies poured billions of dollars into anti-amyloid Alzheimer research. They were incredibly successful at creating drugs to lower this sticky brain peptide. But dramatically reducing amyloid plaque buildup in the brains of patients with dementia does not seem to reverse decline. A new study in the journal Cell (December 11, 2025) reveals that an old shingles vaccine (>Zostavax) not only prevents or delays a diagnosis of dementia, it may also “reduce disease progression among those living with dementia.” Such results are extraordinary. 

    Anti-Amyloid Dominates Center Stage:

    While most of the Alzheimer disease funding was devoted to amyloid research, a small group of investigators was beginning to explore the idea that amyloid buildup in the brain was a reaction to infection. In other words, amyloid could be part of the body’s immune reaction to pathogen invasion. It might be initially trying to protect the brain, but eventually runs amok and causes harm.We have written extensively about a handful of scientists who began asking whether viruses might be culprits contributing to cognitive decline. In particular they were concerned about herpes viruses such as varicella-zoster (the virus that causes chickenpox and shingles) and herpes simplex type 1 (the virus that causes cold sores). They were asking an unpopular question: Are viruses (or other pathogens) lighting the match that eventually burns the brain down? Most neuroscientists ignored that question. It was far easier to hop on the anti-amyloid bandwagon. That’s where the money was. And the FDA went along. It approved three anti-amyloid medications. You can read our analyses of that decision at these links:“YIKES! FDA Approves Lecanemab Against Alzheimer’s” Another Huge Anti-Amyloid Drug Failure Against Alzheimer’s! “Herpes Hypothesis? Antiviral Herpes Drugs vs. Alzheimer Disease?”  Show 1451: Rethinking Dementia: Is What We Believed about Alzheimer’s Wrong? 

    New Research Strengthens the Story of Vaccines vs. Dementia:

    Shingles Vaccine May Actually Slow Dementia Progression—Even After Diagnosis When we first reported on the connection between shingles vaccines and dementia prevention, the news was already exciting. Now there’s even better news: the shingles vaccine might help people who already have dementia. The study published this week in the journal Cell (December 11, 2025) suggests that the herpes zoster (shingles) vaccine doesn’t just reduce the risk of developing dementia—it may actually slow down the disease once someone has it. According to the research, people with dementia who received the shingles vaccine were almost 30 percent less likely to die from dementia over a nine-year period.

    The Researchers Describe Their Results:

     “We found that live-attenuated HZ [herpes zoster] vaccination [Zostavax] reduced both new diagnoses of MCI [mild cognitive impairment] among those without any record of cognitive impairment and deaths due to dementia among patients living with dementia. The HZ vaccine thus appears to have a beneficial effect at both ends of the clinical disease course of dementia. “Our findings suggest that HZ vaccination could be an effective intervention to prevent or delay MCI and dementia, as well as to reduce disease progression among those living with dementia. Such a beneficial effect also appears to exist among those who already have more advanced dementia, based on our finding that the reductions in deaths due to dementia from HZ vaccination tended to be larger among those with more versus less severe dementia.” Building On Prior Studies That Explored the Role of Vaccines Against Dementia: The latest research builds on groundbreaking studies we’ve been following closely. Earlier this year, research published in Nature (April 2, 2025) and JAMA (April 23, 2025) revealed that the shingles vaccine reduced dementia diagnoses by 20 percent over seven years.

    We were so intrigued that we interviewed the lead scientist, Dr. Pascal Geldsetzer of Stanford University Medicine, on our nationally syndicated radio show. You can listen to our original interview with him at this link:

    Show 1394: Viruses, Vaccines and Alzheimer Disease 

    The original studies took advantage of what scientists call “natural experiments.” In Wales, people born before September 2, 1933 were never eligible for the free shingles vaccine, while those born on or after that date were eligible. In Australia, a similar cutoff occurred at age 80 when the country launched its shingles vaccination program in November 2016.

    These natural experiments are powerful because they compare people who are virtually identical except for their vaccination status. It’s about as close as researchers can get to a randomized controlled trial without actually running one.

    Why the New Study in Cell is So Intriguing: The new Cell article has grabbed headlines because it examined what happens earlier in the disease process and what happens to people already diagnosed with dementia. The idea that an older, not super effective shingles vaccine could both prevent the disease and make a difference even after someone is diagnosed is impressive. If one of the anti-amyloid drugs did both of those things, drug companies would be jumping for joy and charging an arm and a leg for such treatment. Even more remarkable, among people already living with dementia, those who had received the shingles vaccine had fewer deaths due to dementia. This suggests the vaccine may be slowing the progression of an already established disease.

    Two Vaccines Against Dementia: Zostavax vs. Shingrix

    The most recent research was based on the older shingles shot,Zostavax. It is no longer available. The newer shingles vaccine is called Shingrix and requires 2 shots. No vaccine is perfect, but Shingrix is substantially more effective at warding off a shingles attack than Zostavax.

    A study published in Clinical Infectious Diseases, Feb. 13, 2021 reports that the older live attenuated vaccine [Zostavax]: “…only offered approximately 50% protection against HZ [herpes zoster or shingles.]

    Recombinant zoster vaccine (Shingrix): “…demonstrated a 97.2% reduction in HZ among adults aged 50 and older.”

    Will the newer Shingrix vaccine perform better against dementia than the older Zostavax? No one can say for sure. We might hope that the newer vaccine, Shingrix, would be more effective against dementia, since it is more effective against the virus that causes chicken pox. Because there will never be a head-to-head trial, the answer is unlikely to be revealed. But if you continue to read you will discover some data that look favorable for Shingrix.

    The Loudest Shouters Bet on Anti-Amyloid Drugs: The neuroscience community is a kind of old boys’ network. Once these researchers latched onto amyloid plaque as the cause of Alzheimer disease (AD), they were mostly unwilling to consider other possibilities. We interviewed a key player in uncovering this mess on our radio show # 1416:
    “Exposing Fraud and Arrogance in Alzheimer’s Research” 

    This podcast is worth a listen because we interviewed Dr. Matthew Schrag, a neurologist who has challenged researchers who helped advance the amyloid plaque theory of AD. We also talked with Charles Piller, author of an essay in the New York Times titled “The Devastating Legacy of Lies in Alzheimer’s Science.” His book, DoctoredFraud, Arrogance and Tragedy in the Quest to Cure Alzheimer’s, features Dr. Schrag and describes the way the neuroscience community created the amyloid plaque story that has been hard to budge.

    The Overlooked Herpes Theory of Dementia: There is no doubt that amyloid plaque accumulates in the brains of many patients with Alzheimer disease. But what triggers that amyloid accumulation? Could viruses be one of the pebbles that starts a mountain slide that leads to an avalanche we call dementia? Viral infections cause a lot of mischief! One need look no further than COVID-19 to verify that there can be long-lasting complications after such illnesses. The neuroscience community has long ignored the idea that viruses might play an important role in the development of dementia.

    Over 40 years ago, a pathologist named Melvyn J. Ball, MD, linked herpes simplex virus (HSV) type 1 to Alzheimer dementia. Dr. Ruth Itzhaki of the University of Manchester in England has also been studying the relationship between herpes viruses and Alzheimer disease since the early 1990s. Both of these creative thinkers were mostly ignored by the neuroscience community.


    No comments:

    Post a Comment